Work

Comparison of Ranibizumab and Aflibercept for Neovascular Age-related Macular Degeneration (namd) Using a Treat-and-extend Regimen: Results of the 24-month Secondary Efficacy Outcomes From the Rival Study, a Randomized Clinical Trial